Concordia International (NSDQ:CXRX) said it won pre-market approval from the FDA for its Photofrin 630 laser, which is designed to activate an anti-cancer drug in patients with throat and lung cancers. Oakville, Ontario-based Concordia said the device is designed to activate the drug Photofrin (porfimer sodium) in patients with esophageal cancer, Barrett’s Esophagus and non-small cell lung cancer. […]